Long-term cholinesterase inhibitor treatment of Alzheimer's disease
Long-term cholinesterase inhibitor treatment of Alzheimer's disease
About this item
Full title
Author / Creator
Publisher
Hong Kong: Adis International
Journal title
Language
English
Formats
Publication information
Publisher
Hong Kong: Adis International
Subjects
More information
Scope and Contents
Contents
The most prevalent cause of dementia--Alzheimer's disease--is characterised by an early cholinergic deficit that is in part responsible for the cognitive deficits, especially memory and attention defects, seen with this condition. Three cholinesterase inhibitors (ChEIs), namely donepezil, rivastigmine and galantamine, are widely used for the sympto...
Alternative Titles
Full title
Long-term cholinesterase inhibitor treatment of Alzheimer's disease
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_66896435
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_66896435
Other Identifiers
ISSN
1172-7047
E-ISSN
1179-1934
DOI
10.2165/00023210-200418120-00001
